About BridgeLine
Every plan is built to the standard we'd expect if we were the ones evaluating it.
Most biotech programs don't stall because the science is weak. They stall because the preclinical plan wasn't built to drive decisions, or the story wasn't ready when the diligence call came. BridgeLine exists to change that.
Complimentary | 30 minutes
Timothy S. Luongo, PhD, MSTR
Founder and Principal
Tim built BridgeLine after 15+ years in academia and the genetic medicines and biologics industry. He designed preclinical programs, evaluated companies from the acquirer's side, and saw firsthand how promising science stalls for fixable reasons.
Built IND-enabling programs as an operator at Spark Therapeutics (Roche) and StrideBio, and evaluated companies from the buy side at Sarepta on transactions valued up to $11B, supported by a network of subject matter experts across regulatory affairs, CMC, and commercial strategy.
Earlier in his career, he worked at Cephalon (now Teva) and trained at Temple University, the NIH Vaccine Research Center, and the University of Pennsylvania, generating mechanistic and translational insights published in high-impact journals including Nature, Cell, Immunity, and Circulation. He holds a PhD from Temple University, a Master of Science in Translational Research (Drug Development and Regulatory Affairs) from UPenn, and a BS in Biochemistry from Eastern University.
Today, he uses that combined foundation to help biotech teams accelerate IND timelines and advance into early clinical development, avoid costly study redesigns, and close funding rounds with stronger scientific narratives.
Why Companies Choose BridgeLine
vs. Hiring a Head of Preclinical/Nonclinical or R&D
A senior hire takes 4-6 months to recruit and costs $300K+ in salary and equity. BridgeLine starts within 2 weeks and delivers the same caliber of strategic output. For teams that are not ready for a full-time head, fractional support provides continuous leadership without the overhead or the equity dilution.
vs. Big Consulting Firms
BridgeLine delivers protocol-level specificity: CRO shortlists, study-by-study budgets, and sequencing with go/no-go gates. Not 80-page strategy decks written by analysts who have never designed an IND-enabling program. Every engagement is led by someone who has actually built the programs at Spark and evaluated the acquisitions at Sarepta.
vs. CROs
CROs execute your studies. BridgeLine decides which studies to run, in what order, with what success criteria, and at which CROs. No conflict of interest. When a CRO recommends an additional study, you want someone independent who can tell you whether it is actually needed or whether it is incremental revenue for the CRO.
vs. Doing It Internally
Makes sense if someone on your team has designed IND-enabling programs across multiple modalities and evaluated programs from the acquirer's side. If not, a Strategy Diagnostic ($3,500-$5,000) gives you that perspective in 1-2 weeks: scored findings, gap analysis, and clear next steps. 100% credits toward a core engagement.
How BridgeLine Works
The operating standard behind every engagement.
Deliverables Built to Survive Real Questions
A preclinical roadmap from BridgeLine includes the specific CROs, the study sequence with go/no-go gates, the budget by study, and the regulatory strategy. When an investor asks "why this model?" or "what happens if the tox study fails?", the answer is already in the document. That is what "built to survive diligence" means in practice.
Founder-Led, Every Engagement
Tim is the person on the call, reviewing the protocol, building the timeline, and presenting to your board. The same person who designed IND-enabling programs at Spark and evaluated acquisition targets at Sarepta. No junior handoff, no account manager layer.
Walk Into Any Room With It
Deliverables include visual Gantt timelines, study-by-study budget tables, scored risk registers with mitigations, and executive summaries written for non-scientists. One client took a Preclinical Roadmap directly into a Series A pitch without changing a slide. That is the standard.
What a New Client Can Expect
- A complimentary 30-minute Strategy Call where Tim assesses your program and recommends a specific starting point
- A written scope with timeline, deliverables, and price before any commitment
- Deliverables you can put in front of your board, your investors, or a pharma BD team without reformatting
- Direct access to Tim throughout the engagement. The person who scoped it is the person who delivers it.
- 100% of a Strategy Diagnostic fee credited toward any core engagement, valid 9 months
What Clients Have Said About Working With BridgeLine
From founders, CSOs, and BD leads at companies ranging from seed-stage to large pharma, who have worked directly with Tim on preclinical strategy, portfolio decisions, and diligence preparation.
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
See If BridgeLine Is the Right Fit for Your Program
Book a complimentary Strategy Call. In 30 minutes, BridgeLine will assess your situation and recommend the right starting point, whether that is a diagnostic, a core engagement, or advisory support.
Book a Strategy CallComplimentary · 30 minutes · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com